Advanced NSCLC Patients at the Extremes of Age in the Era of EGFR-TKIs

被引：0
|
作者：
Chen, Yu-Mu [1 ]
Lai, Chien-Hao [2 ]
Chang, Huang-Chih [3 ]
Chao, Tung-Ying [3 ]
Tseng, Chia-Cheng [2 ]
Fang, Wen-Feng [2 ]
Chung, Yu-Hsiu [2 ]
Wang, Yi-Hsi [2 ]
Su, Mao-Chang [2 ]
Huang, Kuo-Tung [2 ]
Wang, Chin-Chou [2 ]
Lin, Meng-Chih [2 ]
机构：
[1] Kaohsiung Chang Gung Mem Hosp, Kaohsiung, Taiwan
[2] Chang Gung Mem Hosp Kaohsiung, Kaohsiung, Taiwan
[3] Kaohsiung Chang Gung Mem Hosp, Pulmonary & Crit Care Med, Kaohsiung, Taiwan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
Extreme age; non-small cell lung cancer; Tyrosine kinase inhibitors;
D O I：
10.1016/j.jtho.2016.11.1971
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PUB001
引用
收藏
页码：S1445 / S1445
页数：1
相关论文
共 50 条
  • [1] Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
    Wen, Miaomiao
    Xia, Jinghua
    Sun, Ying
    Wang, Xuejiao
    Fu, Xianghui
    Zhang, Yanning
    Zhang, Zhipei
    Zhou, Yongan
    Li, Xiaofei
    [J]. BIOLOGICS-TARGETS & THERAPY, 2018, 12 : 183 - 190
  • [2] Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
    Wei, Zhigang
    Ye, Xin
    Yang, Xia
    Zheng, Aimin
    Huang, Guanghui
    Li, Wenhong
    Wang, Jiao
    Han, Xiaoying
    Meng, Min
    Ni, Yang
    [J]. ONCOTARGET, 2017, 8 (34) : 56714 - 56725
  • [3] Combination of EGFR-TKIs with Chemotherapy versus EGFR-TKIs alone in EGFR-Mutant Advanced NSCLC with Concomitant Genetic Alterations
    Feng, W.
    Gu, W.
    Zhang, H.
    Lu, Y.
    Gu, W.
    Li, M.
    Yang, S.
    Zhang, J.
    Ye, Z.
    Lin, Q.
    Liang, Y.
    Chen, H.
    Cheng, Y.
    Yao, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S622 - S622
  • [4] Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
    Guowei Zhang
    Ruirui Cheng
    Zengli Zhang
    Tao Jiang
    Shengxiang Ren
    Zhiyong Ma
    Sha Zhao
    Caicun Zhou
    Jun Zhang
    [J]. Scientific Reports, 7
  • [5] Progression patterns at RECIST PD during EGFR-TKIs in advanced NSCLC patients harboring EGFR mutation
    Yoshida, Tatsuya
    Yoh, Kiyotaka
    Goto, Koichi
    Matsumoto, Shingo
    Umemura, Shigeki
    Niho, Seiji
    Ohmatsu, Hironobu
    Ohe, Yuichiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
    Zhang, Guowei
    Cheng, Ruirui
    Zhang, Zengli
    Jiang, Tao
    Ren, Shengxiang
    Ma, Zhiyong
    Zhao, Sha
    Zhou, Caicun
    Zhang, Jun
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [7] Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study
    Huang, Chu-ying
    Wang, Li
    Feng, Cheng-jun
    Yu, Ping
    Cai, Xiao-hong
    Yao, Wen-xiu
    Xu, Yong
    Liu, Xiao-ke
    Zhu, Wen-jiang
    Wang, Yan
    Zhou, Jin
    Lu, You
    Wang, Yong-sheng
    [J]. ONCOTARGET, 2016, 7 (41): : 66480 - 66490
  • [8] Rebiopsy of advanced NSCLC after EGFR-TKIs treatment: A systematic review
    Imakita, T.
    Kataoka, Y.
    Matsumoto, H.
    Morisawa, T.
    Sakurai, A.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [9] Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
    Zhang, Chengjuan
    Wei, Bing
    Li, Peng
    Yang, Ke
    Wang, Zhizhong
    Ma, Jie
    Guo, Yongjun
    [J]. PLOS ONE, 2017, 12 (03):
  • [10] Evolving therapeutic landscape of EGFR-TKIs in NSCLC
    Feng, Chenfeina
    Li, Rendong
    Li, Xiaolei
    Xu, Xinping
    [J]. MCB Molecular and Cellular Biomechanics, 2024, 21
12345